Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease

Díaz-Corrales, Francisco J.; Viedma, S. Sanz; García-Solís, David; Escobar-Delgado, Teresa; Mir, Pablo

doi:10.1007/s00259-009-1289-4

Cited by 57 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such a drug-exacerbated parkinsonism may represent patients at a prodromal state of PD who do not tolerate the offending medication. Furthermore, it has concordantly been reported that in patients suspected of having drug-induced PS who, however, presented with pathologic DAT binding, either neurodegenerative PS alone or a combination of neurodegenerative and drug-induced PS was finally determined to be present (45,(59)(60)(61).…”

Section: Drug-induced Psmentioning

confidence: 63%

Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

2013

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the radiopharmaceuticals used to evaluate nigrostriatal dopamine imaging; (2) the pattern of uptake of these radiopharmaceuticals in parkinsonian syndromes; and (3) the role of these radiopharmaceuticals in the evaluation of parkinsonian syndromes.Financial Disclosure: Dr. Tatsch is a meeting participant/lecturer for GE Healthcare. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, participants can access this activity through the SNMMI Web site (http:// www.snmmi.org/ce_online) through August 2016.This article gives an update on nigrostriatal dopamine terminal imaging, with emphasis on SPECT performed with the presynaptic dopamine transporter (DAT) ligand 123 I-FP-CIT. The paper covers the rational use of this technique in the diagnostic work-up of patients with known or suspected parkinsonian syndromes. In detail, it addresses the impact of the method for the proof or exclusion of neurodegenerative parkinsonism, for its early and preclinical diagnosis, and for the evaluation of disease progression. The importance of normal DAT binding for differentiating symptomatic parkinsonism and relevant tremor syndromes from neurodegeneration is highlighted. Particularly emphasized is the role of DAT SPECT for diagnosing Lewy body dementia and its separation from Alzheimer dementia. Finally, some remarks deal with the economic aspects of the use of these imaging techniques in the clinical setting.

show abstract

Section: Drug-induced Psmentioning

confidence: 63%

Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

2013

View full text Add to dashboard Cite

show abstract

“…In FTD patients, where neuroleptics are widely used to assist with behavior disorders, it is important to differentiate between Parkinsonism with underlying neurodegenerative pathology and a drug-induced syndrome. The uptake of tracer is normal in drug-induced Parkinsonism, and an abnormal image supports the diagnosis of dopaminergic system neurodegeneration [82]. Unfortunately, neuroimaging of the dopaminergic system has cannot differentiate between PD and atypical Parkinsonism well [77].…”

Section: Neuroimaging In Ftd With Parkinsonismmentioning

confidence: 99%

Parkinsonian syndrome in familial frontotemporal dementia

Siuda¹,

Fujioka²,

Wszołek³

2014

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Parkinsonism in frontotemporal dementia (FTD) was first described in families with mutations in the microtubule-associated protein tau (MAPT) and progranulin (PRGN) genes. Since then, mutations in several other genes have been identified for FTD with Parkinsonism, including chromosome 9 open reading frame 72 (C9ORF72), chromatin modifying protein 2B (CHMP2B), valosin-containing protein (VCP), fused in sarcoma (FUS) and transactive DNA-binding protein (TARDBP). The clinical presentation of patients with familial forms of FTD with Parkinsonism is highly variable. The Parkinsonism seen in FTD patients is usually characterized by akinetic-rigid syndrome and is mostly associated with the behavioral variant of FTD (bvFTD); however, some cases may present with classical Parkinson’s disease. In other cases, atypical Parkinsonism resembling progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS) has also been described. Although rare, Parkinsonism in FTD may coexist with motor neuron disease. Structural neuroimaging, which is crucial for the diagnosis of FTD, shows characteristic patterns of brain atrophy associated with specific mutations. Structural neuroimaging is not helpful in distinguishing among patients with parkinsonian features. Furthermore, dopaminergic imaging that shows nigrostriatal neurodegeneration in FTD with Parkinsonism cannot discriminate parkinsonian syndromes that arise from different mutations. Generally, Parkinsonism in FTD is levodopa unresponsive, but there have been cases where a temporary benefit has been reported, so dopaminergic treatment is worth trying, especially, when motor and non-motor manifestations can cause significant problems with daily functioning. In this review, we present an update on the clinical and genetic correlations of FTD with Parkinsonism.

show abstract

“…Algunos estudios han comprobado que este grupo, además de la retirada del fármaco, se beneficia del tratamiento con levodopa 8,17 , por lo que su identificación precoz es importante. Desgraciadamente, la similitud clínica existente entre un parkinsonismo iatrogénico puro (PY) y un parkinsonismo neurodegenerativo 8,[18][19][20] , incluido el PSEF, dificulta la identificación solo con aquella, por lo que, en muchas ocasiones, se hace necesario recurrir a pruebas complementarias para establecer el diagnóstico.…”

Section: Introductionunclassified

“…En la actualidad, la tomografía por emisión de fotón simple con 123 Ioflupano, también conocida como SPECT [ 123 I]FP-CIT o DaT-SCAN, es la prueba de referencia para el diagnóstico diferencial entre PRF y otros parkinsonismos neurodegenerativos 8,18,19,[21][22][23] . El PY aparece como consecuencia del bloqueo que los fármacos provocan en los receptores dopaminérgicos, sin que la vía estriatonígrica se vea afectada y, por tanto, sin que se altere la captación del radiotrazador [17][18][19][24][25][26] .…”

Section: Introductionunclassified

“…El PY aparece como consecuencia del bloqueo que los fármacos provocan en los receptores dopaminérgicos, sin que la vía estriatonígrica se vea afectada y, por tanto, sin que se altere la captación del radiotrazador [17][18][19][24][25][26] . Por el contrario, los parkinsonismos neurodegenerativos, incluido el PSEF, sufren alteración en la captación del radiotrazador [17][18][19] .…”

Section: Introductionunclassified

See 1 more Smart Citation

Utilidad de la tomografía por emisión de fotón simple con 123Ioflupano en el diagnóstico del parkinsonismo relacionado con fármacos. Estudio prospectivo

Romero

Padillo

2013

Neurología

View full text Add to dashboard Cite

show abstract

Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease

Abstract: DIP and PD are difficult to differentiate based on clinical signs. The precision of clinical diagnosis could be reliably enhanced by (123)I-FP-CIT SPECT imaging.

Cited by 57 publications

References 21 publications

Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

Parkinsonian syndrome in familial frontotemporal dementia

Utilidad de la tomografía por emisión de fotón simple con 123Ioflupano en el diagnóstico del parkinsonismo relacionado con fármacos. Estudio prospectivo

Contact Info

Product

Resources

About